Conclusion: In this nationally representative survey sample of adults in the U.S., the prevalence rates of gout and hyperuricemia remained substantial, albeit unchanged, between 2007 and 2016. Despite these rates, only one-third of gout patients were receiving urate-lowering therapy.
These data indicate that although the prevalence rates of gout and hyperuricemia have plateaued over the past decade, their frequency and burden remain substantial, especially with ongoing population growth and aging.
The researchers also conclude that in the general population, male sex, obesity, chronic kidney disease and thiazide diuretic use were risk factors for failing to reach a therapeutic target serum urate level, suggesting the potential need for a more aggressive approach within these groups.
Excerpted and adapted from:
Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019 June;71(6):991–999.
